Search by Drug Name or NDC
NDC 49702-0246-61 Dovato 50; 300 mg/1; mg/1 Details
Dovato 50; 300 mg/1; mg/1
Dovato is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ViiV Healthcare Company. The primary component is DOLUTEGRAVIR SODIUM; LAMIVUDINE.
MedlinePlus Drug Summary
The combination of dolutegravir and lamivudine is used alone to treat human immunodeficiency virus (HIV) infection in certain people who have never been treated with any HIV medications before or in certain people who have responded well to their HIV medication regimens and have no history of poor response to their past HIV regimens. Lamivudine is in a class of medications called nucleoside analogue reverse transcriptase inhibitors (NRTIs) and dolutegravir is in a class of medications called integrase strand transfer inhibitors (INSTIs). They work together to decrease the amount of HIV in your blood. Although dolutegravir and lamivudine will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of getting or transmitting the HIV virus to other people.
Related Packages: 49702-0246-61Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Dolutegravir and Lamivudine
Product Information
| NDC | 49702-0246 |
|---|---|
| Product ID | 49702-246_c29f6087-381e-440e-ab90-b71e3b560f58 |
| Associated GPIs | 12109902260320 |
| GCN Sequence Number | 079638 |
| GCN Sequence Number Description | dolutegravir sodium/lamivudine TABLET 50MG-300MG ORAL |
| HIC3 | W0K |
| HIC3 Description | ANTIRETROVIRAL-INTEGRASE INHIBITOR AND NRTI COMB. |
| GCN | 46175 |
| HICL Sequence Number | 045679 |
| HICL Sequence Number Description | DOLUTEGRAVIR SODIUM/LAMIVUDINE |
| Brand/Generic | Brand |
| Proprietary Name | Dovato |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | dolutegravir sodium and lamivudine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 50; 300 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | DOLUTEGRAVIR SODIUM; LAMIVUDINE |
| Labeler Name | ViiV Healthcare Company |
| Pharmaceutical Class | HIV Integrase Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibit |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA211994 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49702-0246-61 (49702024661)
| NDC Package Code | 49702-246-61 |
|---|---|
| Billing NDC | 49702024661 |
| Package | 14 TABLET, FILM COATED in 1 BOTTLE (49702-246-61) |
| Marketing Start Date | 2019-08-06 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |